CDKN2A and differentiated thyroid carcinoma: CDKN2A’s deletion has been previously reported to be associated with poor survival in anaplastic thyroid cancer or advanced differentiated thyroid cancers patients and poorest thyroid differentiation, which is consistent with our results (Yoshihara et al., 2013).